5). In views of the unselective binding specificity of CpGPTO-induced immunoglobulin (Fig. 6b,c), we argued that binding of CpGPTO to the antigen receptor could drive a ‘PTO- or DNA-reactive’ B-cell subset into receptor revision as reported previously.[31] Intriguingly, high expression of RAG-1 and Ku70 marked a subpopulation of CpGPTO-induced B-cell blasts as cells prone for receptor revision that were shown to originate from IgM+ CD27+ B cells (Fig. 6a). Although the concept that IgM memory B cells undergo receptor revision is controversial, the physiological antigen

promiscuity of the IgM receptor underscores that receptor revision in these cells could be beneficial. Moreover, it is well-acknowledged that marginal zone SB203580 ic50 B cells (discussed as murine counterparts of human peripheral blood IgM+ CD27+ B cells) are strongly responsive to TLR stimulation.[47-50] Nevertheless, it was recently suggested that CpGPTO induces proliferation of transitional B cells,[51] a B-cell subset expressing polyreactive IgM and sensitive to treatment with syk inhibitors.[52] Albeit the frequency of these cells in freshly isolated peripheral blood B cells from the donors

used in this study was very low (0·1–1%), and blast formation was not observed in the CD27– fraction (Fig. 6a), we cannot exclude transitional B cells as the target subpopulation undergoing TLR9-induced receptor revision. Further studies will be needed to answer this question. Taken together, our data provide evidence R788 price that TLR9 can participate in receptor revision. This was demonstrated for LC rearrangement (Fig. 5) but could also affect VH element replacement.[53, 54] Our study further suggests that CpGPTO can be used to study receptor revision

triggered by chromatin-bearing autoantigens. It can, however, only be speculated how TLR9 affects receptor Tyrosine-protein kinase BLK revision in vivo: TLR9 could contribute to exceeding a certain activation threshold necessary to tackle receptor revision or could act as a sensor for chromatin-bearing autoantigens, subsequently licensing receptor revision. Hence, a strong and long-lasting B-cell stimulus such as CpGPTO in vitro or that occurring in vivo, i.e. in autoimmune diseases (or possibly that upon CpGPTO administration) could trigger receptor revision in the periphery in the attempt to correct or eliminate autoreactivity as physiologically seen in the bone marrow. Nonetheless, in the periphery this process might result in increased autoreactivity of the immunoglobulin in predisposed individuals. In earlier studies receptor revision is, therefore, viewed as a pathological event. Our results, describe a mechanism possibly contributing to severe adverse events after CpGPTO treatment. Nevertheless, we can only speculate that the observations made in vitro could be associated with the manifestation of autoimmunity in vivo, e.g. the triggering of Wegener granulomatosis reported in the CpGPTO-adjuvanted hepatitis B vaccination trial.